WO2022194781 - HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
National phase entry:
Publication Number
WO/2022/194781
Publication Date
22.09.2022
International Application No.
PCT/EP2022/056551
International Filing Date
14.03.2022
Title **
[English]
HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS
[French]
DÉRIVÉS HÉTÉROCYCLIQUES COMME INHIBITEURS DE JANUS KINASE
Applicants **
CHIESI FARMACEUTICI S.P.A.
Inventors
ACCETTA, Alessandro
RANCATI, Fabio
RIZZI, Andrea
CUZZOLIN, Alberto
MESIĆ, Milan
ŽIHER, Dinko
ELENKOV, Ivaylo
BUTKOVIĆ, Kristina
Priority Data
21162515.7
15.03.2021
EP
21217278.7
23.12.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3316 | |
| EPO | Filing, Examination, Granting | 13793 | |
| Japan | Filing, Examination, Granting | 2118 | |
| South Korea | Filing, Examination, Granting | 1951 | |
| USA | Filing, Examination, Granting | 6090 |
Total:
27,268
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.[French]
La présente invention concerne un composé de formule générale (I) inhibant la famille JAK des protéines kinases à tyrosine non réceptrices (JAK1, JAK2, JAK3 et TYK2) ; des procédés de préparation de tels composés, des compositions pharmaceutiques les contenant et leur utilisation thérapeutique. Les composés de l'invention peuvent être utiles dans le traitement de maladies ou d'états associés à un dérèglement des kinases non réceptrices de la famille JAK ; en particulier pour le traitement de diverses maladies inflammatoires, notamment l'asthme, la BPCO et d'autres maladies respiratoires.